Intuitive Surgical, Inc. (NASDAQ:ISRG) Stake Cut by Wambolt & Associates LLC

Wambolt & Associates LLC decreased its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 8.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 987 shares of the medical equipment provider’s stock after selling 90 shares during the period. Wambolt & Associates LLC’s holdings in Intuitive Surgical were worth $431,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the stock. Gilbert & Cook Inc. grew its holdings in shares of Intuitive Surgical by 6.5% during the 4th quarter. Gilbert & Cook Inc. now owns 3,437 shares of the medical equipment provider’s stock valued at $1,160,000 after acquiring an additional 211 shares in the last quarter. Cary Street Partners Investment Advisory LLC grew its stake in Intuitive Surgical by 172.4% in the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 779 shares of the medical equipment provider’s stock valued at $263,000 after purchasing an additional 493 shares in the last quarter. Dimensional Fund Advisors LP increased its position in Intuitive Surgical by 0.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 519,807 shares of the medical equipment provider’s stock worth $175,364,000 after purchasing an additional 4,335 shares during the last quarter. Avantax Advisory Services Inc. raised its stake in shares of Intuitive Surgical by 4.4% during the 4th quarter. Avantax Advisory Services Inc. now owns 9,508 shares of the medical equipment provider’s stock worth $3,208,000 after purchasing an additional 403 shares in the last quarter. Finally, Moran Wealth Management LLC acquired a new stake in shares of Intuitive Surgical during the 4th quarter valued at about $245,000. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, EVP Robert Desantis sold 376 shares of the stock in a transaction on Monday, July 29th. The shares were sold at an average price of $446.60, for a total value of $167,921.60. Following the completion of the transaction, the executive vice president now owns 5,506 shares in the company, valued at approximately $2,458,979.60. The sale was disclosed in a filing with the SEC, which is available at this link. In related news, EVP Robert Desantis sold 376 shares of the business’s stock in a transaction on Monday, July 29th. The stock was sold at an average price of $446.60, for a total value of $167,921.60. Following the sale, the executive vice president now owns 5,506 shares of the company’s stock, valued at approximately $2,458,979.60. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Henry L. Charlton sold 40,243 shares of the stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $486.84, for a total value of $19,591,902.12. Following the transaction, the senior vice president now owns 3,001 shares of the company’s stock, valued at $1,461,006.84. The disclosure for this sale can be found here. Insiders have sold 50,555 shares of company stock worth $24,267,737 over the last 90 days. Corporate insiders own 0.90% of the company’s stock.

Intuitive Surgical Stock Performance

Shares of ISRG opened at $490.93 on Thursday. Intuitive Surgical, Inc. has a 52 week low of $254.85 and a 52 week high of $493.97. The firm has a market capitalization of $174.13 billion, a P/E ratio of 88.62, a P/E/G ratio of 5.20 and a beta of 1.39. The company has a 50-day simple moving average of $461.63 and a 200-day simple moving average of $420.33.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. The company had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The company’s quarterly revenue was up 14.5% on a year-over-year basis. During the same quarter last year, the company earned $1.18 EPS. As a group, equities analysts forecast that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Wall Street Analyst Weigh In

ISRG has been the topic of several recent research reports. Truist Financial raised their price objective on shares of Intuitive Surgical from $450.00 to $515.00 and gave the company a “buy” rating in a research report on Tuesday, July 16th. Morgan Stanley upped their price objective on shares of Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. BTIG Research boosted their price target on Intuitive Surgical from $469.00 to $494.00 and gave the stock a “buy” rating in a research report on Wednesday, August 28th. Robert W. Baird upped their price target on Intuitive Surgical from $487.00 to $503.00 and gave the stock an “outperform” rating in a research note on Friday, July 19th. Finally, Citigroup raised their price objective on Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a research note on Thursday, August 22nd. Six research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $446.45.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.